AI Consensus Investment Thesis
Regeneron Pharmaceuticals (REGN) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
No Action - Keep Monitoring
One horizon is weak; wait for clearer confirmation.
1-Year
PARTIALLY SELL$707
-11.3%-11.0% incl. dividends5-Year
NEUTRAL$1,049
+31.6%+34.1% incl. dividendsLatest flagship insight
Why Smart Money Is Quietly Accumulating This Debt Free Biopharma Cash Machine
Input reports show sharp divergence regarding long-term operating margins, yet high consensus on the firm's exceptional balance sheet strength and robust free cash flow. While legacy franchise erosion presents a persistent headwind, aggressive share buybacks and a massive, self-funded research pipeline provide a durable compounding floor.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The underlying asset represents an exceptionally resilient, self-funding biopharmaceutical compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry that is fundamentally insulated from macroeconomic volatility and credit market stress. While the broader market overemphasizes near-term top-line deceleration and legacy patent cliffs, the core investment thesis rests on robust owner economics, an unleveraged balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry, and aggressive share count cannibalization. This financial engineeringfinancial engineeringThe design or restructuring of financing, capital allocation, derivatives, taxes, or accounting exposures to achieve a financial objective.View full glossary entry, paired with a highly productive research engine, drives double-digit per-share earnings growth independent of cyclical macroeconomic headwindsmacroeconomic headwindsBroad economic forces that can slow activity, weaken demand, or pressure financial performance.View full glossary entry.
Key insights
- Pristine capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry with near-zero leverage completely neutralizes refinancing risks in a structurally higher-for-longer interest rate regimeinterest rate regimeA persistent pattern in policy rates and market yields that shapes borrowing costs, discount rates, and asset values.View full glossary entry.
- Relentless share repurchases deploy massive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry to aggressively shrink the outstanding equity floatfloatThe number of shares available for public trading in the market.View full glossary entry, providing a strong, reliable valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry.
- The proprietary genomic database and AI-driven discovery platform structurally accelerate pipeline development and lower clinical failure rates.
- Legacy franchise erosion is successfully mitigated by high-dose formulation transitions and global expansion of core immunology blockbusters.
- Severe regulatory price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry, active federal litigation, and unexpected clinical trial setbacks represent the primary long-term downside tail risks.
- Strategic domestic manufacturing infrastructure provides a significant geopolitical moat, shielding operations from international supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry disruptions.
- Valuation multiples are expected to structurally re-rate upward as the market gradually recognizes the durability of the diversified pipeline.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The dominant market narrative treats the asset as a mature, ex-growth biopharmaceutical company facing an inevitable patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry. The crowd and financial media are heavily focused on the competitive erosion of the legacy ophthalmology franchise by biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry and rival therapies. Additionally, there is widespread concern regarding political headwinds, specifically drug pricing mandates and regulatory price caps. Analysts generally view the massive research and development expenditures as a defensive, margin-compressing burden rather than an offensive driver. Consequently, the consensus trade remains cautious, anchoring on near-term top-line stagnation and pricing the stock at a discounted multiple that reflects fears of structural declinestructural declineA long-term weakening trend caused by persistent business or industry headwinds.View full glossary entry.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's systematic mispricing of the asset's structural cash-flow durability and capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry efficiency. While the crowd fixates on top-line growth and legacy patent cliffs, they overlook the mathematical certainty of a massive net buyback yield compounding within an unleveraged financial fortressfinancial fortressA strong balance sheet with low debt and high liquidity, providing resilience against economic downturns.View full glossary entry. The business does not require explosive organic growthorganic growthThe rate at which a company expands revenue through internal operations rather than acquisitions.View full glossary entry to deliver immense shareholder value; its robust free cash flow marginsfree cash flow marginsThe percentage of revenue converted into cash after accounting for capital expenditures and operating costs.View full glossary entry allow it to aggressively retire its own discounted shares. Furthermore, the market treats the substantial research and development budget as a liability, failing to recognize it as an AI-enabled computational biology engine that utilizes unparalleled genomic datasets to structurally lower drug discovery costs and accelerate pipeline renewal.
Repricing Catalyst
What could make the market recognize and close that gap? The convergence of the crowd narrative with the intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry thesis will be triggered by consecutive quarters of robust free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry that demonstrate successful stabilization of the ophthalmology franchise, proving the defensive moat is intact. This operational validation, paired with pivotal late-stage clinical readouts in the oncology and metabolic pipelines, will force sell-side analysts to revise their terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry assumptions. Additionally, a visible acceleration in share retirements and the resolution of outstanding regulatory litigation will eliminate key overhangs, forcing a market-wide multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry as the crowd abandons the value-trap narrative.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Mixed
- Volatility
- Moderate
- Cycle position
- Early Discovery
Reports agree on a moderate volatility regime but diverge on the convergence cycle position, with some identifying early discovery of the asset's AI-driven data moatdata moatA durable competitive advantage created by proprietary, difficult-to-replicate, or continuously improving data.View full glossary entry, while others view it as a reversal phase due to near-term pipeline setbacks and regulatory litigation.
Macro Regime Fit
Does the current market environment support the thesis? The current macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of higher-for-longer interest rates, tight liquidity, and persistent stagflationary pressuresstagflationary pressuresEconomic pressures created when weak growth and persistent inflation occur together.View full glossary entry acts as a powerful tailwind for this asset. While expensive capital and credit stress severely punish highly leveraged, cash-burning competitors, this unleveraged enterprise self-funds its operations and massive research budget entirely through organic cash generation. Furthermore, the non-discretionary nature of its therapeutic portfolio provides extreme demand inelasticity, shielding earnings from cyclical consumer downturns. Geopolitical supply-chain fragmentation also favors the company's domestic manufacturing footprint, positioning it as a safe haven for institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports centers on the long-term return on investment of the company's massive research and development budget. Optimistic reports assume a longer investment horizon, viewing the high R&D intensity as a highly accretive, AI-enabled computational biology engine poised to deliver metabolic and oncology breakthroughs. Conversely, cautious reports apply a heavier risk weighting to recent clinical trial failures and assume that elevated fixed costsfixed costsCosts that do not change materially with production or sales volume over a relevant range and period.View full glossary entry will structurally compress operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry. Additionally, there is disagreement regarding the speed of legacy franchise erosion, driven by differing assumptions about biosimilar penetration rates and payer step-therapy mandates.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| DupixentdupixentDupixent is the brand name for dupilumab, a biologic medicine used for several inflammatory conditions.View full glossary entry Franchise Expansion | Innovation And Product | +35% | +40% | DupixentdupixentDupixent is the brand name for dupilumab, a biologic medicine used for several inflammatory conditions.View full glossary entry remains a structural juggernaut, driving robust global sales growth through continuous label expansions into massive indications like COPD and pediatric CSU. This asset acts as a highly durable, compounding cash-flow engine that effectively subsidizes the broader R&D pipeline. Its inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry and clinical superiority ensure top-line resilience regardless of macroeconomic cycles, providing a strong foundation for long-term earnings growth. |
| Aggressive Capital Returncapital returnCash or value distributed to investors, commonly through dividends, share repurchases, or return-of-capital payments.View full glossary entry and Buybacks | Capital Allocation | +20% | +15% | Management intelligently deploys its massive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry to execute aggressive, counter-cyclical share repurchases. By structurally reducing the outstanding share count while trading at a discounted multiple, the company mechanically boosts per-share earnings and intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry. This relentless cannibalization provides a strong valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry and protects long-term shareholders from market volatility. |
| Fortress Balance Sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry in Tightening Regime | Macroeconomic And Macrofinancial | +15% | +10% | Operating with near-zero debt and substantial cash reserves, the company is completely insulated from the rising cost of capitalcost of capitalCost of capital is the required return investors demand to fund a business, project, or asset, reflecting risk and financing mix.View full glossary entry and credit market stress. This financial sovereignty allows the firm to self-fund its massive R&D campaigns and buybacks without relying on external financing, providing a significant competitive advantage over highly leveraged peers. |
| BIOSECURE and Domestic Manufacturing Moat | Political And Geopolitical | +12% | +5.0% | The company's heavily integrated, domestic manufacturing footprint provides a critical strategic advantage under current geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry mandates. While competitors face severe supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry disruptions and transition costs due to restrictions on foreign contract manufacturers, this localized infrastructure ensures uninterrupted production and commands a premium. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Legacy Eylea Franchise Erosion | Competitive Positioning | -18% | -20% | The legacy ophthalmology franchise faces intense competitive pressure from rival therapies and incoming biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry. While high-dose formulations provide a defensive product-cycle extension, the accelerating erosion of the legacy base acts as a persistent drag on top-line growth and suppresses the market's willingness to assign a premium multiple. |
| Regulatory Price Controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry and Pricing Squeeze | Regulatory | -12% | -15% | Bipartisan political pressure and government-mandated drug pricing negotiations represent a structural headwind to peak margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry. These regulatory interventions limit pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and cap the terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry of blockbuster therapies, forcing the company to rely entirely on volume expansion to drive growth. |
| High R&D Capital Intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry | Operational Efficiency | -8.0% | -10% | Defending the biological moat requires massive, structurally high research and development expenditures, which currently consume a significant portion of total revenue. While necessary for long-term pipeline renewal, this heavy investment burden temporarily compresses operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry and increases execution risk if clinical programs face setbacks. |
| Supply Chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry and Input Cost Inflation | Macroeconomic And Macrofinancial | -5.0% | -5.0% | Global energy shocksenergy shockA sudden disruption or price change in energy markets that affects inflation, demand, and operating costs.View full glossary entry and logistics disruptions create persistent cost-push pressures on specialized raw materials and cold-chain distribution. Because regulatory frameworks limit the ability to pass these rising input costsinput costsCosts of labor, materials, energy, components, transport, and services used to produce or deliver an offering.View full glossary entry onto consumers, the company must absorb the difference, resulting in minor gross margin compressiongross margin compressionReduction in profitability due to rising input costs and supply chain expenses.View full glossary entry. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Draconian Regulatory Price Interventions | 25% | -25% | Regulatory | Sudden, aggressive expansion of government price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry or Medicare negotiations targeting core blockbusters would permanently impair the long-term value of the commercial portfolio, severely compressing operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry and halting the buyback engine. |
| Catastrophic High-Dose Eylea Transition Failure | 30% | -25% | Competitive Positioning | If real-world physician adoption of the high-dose formulation stalls or faces aggressive payer step-therapy mandates, the ophthalmology revenue base would collapse rapidly, creating a massive cash-flow deficit before newer pipeline assets can commercialize. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Metabolic Muscle-Preservation Conquest | 35% | +30% | Competitive Positioning | Successful late-stage clinical validation of the company's muscle-preserving candidates as essential adjunct therapies for GLP-1glp 1Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, insulin response, digestion, and appetite.View full glossary entry weight-loss regimens would unlock a massive, unpriced metabolic market. This breakthrough would trigger a rapid upward multiple re-rating as growth investors flood the stock. |
| Costimulatory Bispecific Oncology Breakthrough | 40% | +20% | Innovation And Product | Pivotal Phase 3 clinical outperformance of next-generation oncology assets would establish a highly profitable third pillar of revenue, successfully diversifying the business away from legacy franchise concentration and destroying bear-case structural declinestructural declineA long-term weakening trend caused by persistent business or industry headwinds.View full glossary entry models. |
Company Financial Analysis
Regeneron Pharmaceuticals Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The financial reports agree that the company is a highly resilient cash-generating machine, currently producing over $4 billion in annual free cash flow. While overall revenue growth has slowed down due to competition facing its older eye-care products, this decline is being successfully offset by the explosive growth of its blockbuster immunology drug. Analysts agree that the company's strategy of aggressively buying back its own stock is a highly effective way to boost earnings per share. However, there is a clear disagreement regarding the future outlook for profit margins. Some reports expect earnings to grow steadily as new products launch, while more cautious views warn that heavy spending on research and development, combined with government price limits, will keep a tight lid on future profit growth. Overall, the company's ability to convert sales into pure cash remains a major strength.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 14.3B | USD 4.5B | USD 4.1B |
| 2024 | USD 14.2B | USD 4.4B | USD 3.7B |
| 2023 | USD 13.1B | USD 4B | USD 3.7B |
| 2022 | USD 12.2B | USD 4.3B | USD 4.4B |
| 2021 | USD 16.1B | USD 8.1B | USD 6.5B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.4x | TTM | Native | USD / USD |
| 2024 | 18.4x | TTM | Native | USD / USD |
| 2023 | 25.3x | TTM | Native | USD / USD |
| 2022 | 19.0x | Annual | Native | USD / USD |
| 2021 | 8.9x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company maintains exceptionally high gross margins of around 85%, reflecting the incredible pricing power of its complex biological treatments. However, there is a sharp clash of opinions regarding the future path of operating margins, which have compressed from historical highs down to around 25%. Optimistic reports argue that this margin compression is temporary and represents a deliberate, healthy reinvestment into research and development that will eventually pay off as new high-margin drugs hit the market. In contrast, pessimistic reports argue that the margin decline is structural and permanent, driven by rising competition for older eye-care products, expensive marketing costs, and government-mandated price cuts. While everyone agrees that the company's core products remain highly profitable, the debate over whether profit margins will stabilize or continue to slide remains the key point of disagreement for the future.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 3.6B | 24.9% | 31.4% |
| 2024 | USD 4B | 28.1% | 31.1% |
| 2023 | USD 4B | 30.9% | 30.1% |
| 2022 | USD 5.4B | 44.2% | 35.6% |
| 2021 | USD 8.9B | 55.7% | 50.2% |
Balance sheet and leverage
There is absolute consensus across all reports that the company's balance sheet is an impenetrable fortress. With virtually zero debt and massive cash reserves, the company is completely safe from rising interest rates and credit market stress. This financial safety provides ultimate downside protection for investors. Furthermore, this massive financial firepower gives management incredible flexibility. They can easily fund multi-billion-dollar share buybacks, invest heavily in state-of-the-art domestic manufacturing, and comfortably weather any unexpected legal or regulatory challenges. There is virtually no disagreement on this topic; every analyst views the company's debt-free structure as a massive competitive advantage. In a difficult economic environment where other biotech companies are struggling to borrow money, this company's self-funding ability makes it a highly secure and reliable investment for long-term holders.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 2.7B | USD 8.6B | USD 412.2M net cash | 4.13x |
| 2024 | USD 2.7B | USD 9B | USD 216.2M net debt | 4.73x |
| 2023 | USD 2.7B | USD 10.8B | USD 27.1M net cash | 5.69x |
| 2022 | USD 2.7B | USD 7.7B | USD 404.5M net cash | 5.06x |
| 2021 | USD 2.7B | USD 5.7B | USD 185.9M net cash | 3.56x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company's spending is highly unique because it does not need to invest heavily in traditional physical factories or equipment. Instead, its real "capital expenditure" is its massive research and development budget, which consumes nearly 40% of its total revenue. Reports agree that this heavy spending is a double-edged sword. On the positive side, it completely funds a massive pipeline of over 50 potential new drugs and integrates advanced artificial intelligence into drug discovery, which could lead to future blockbusters. On the negative side, this massive spending acts as a heavy drag on near-term profits. While some analysts view this intense reinvestment as a necessary and highly valuable strategy to outrun patent expirations, others worry it represents inefficient over-investment. Crucially, because the company has no debt, it can fully fund this massive research engine using its own cash.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 898.4M | USD 5.9B |
| 2024 | USD 755.9M | USD 5.2B |
| 2023 | USD 926.4M | USD 4.4B |
| 2022 | USD 590.1M | USD 3.1B |
| 2021 | USD 551.9M | USD 2.6B |
Quarterly Forecast Scenarios
Regeneron Pharmaceuticals Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $615.01 | $669.54 | $686.98 | $736.09 | |
| $590.41 | $684.77 | $728.20 | $724.14 | |
| $560.89 | $698.55 | $757.33 | $713.57 | |
| $549.67 | $706.96 | $795.20 | $723.38 | |
| $566.16 | $728.03 | $811.25 | $716.61 | |
| $549.18 | $747.22 | $843.70 | $738.34 | |
| $527.21 | $763.06 | $852.14 | $746.91 | |
| $537.76 | $786.20 | $892.84 | $771.93 | |
| $559.27 | $801.70 | $912.81 | $782.73 | |
| $570.45 | $829.16 | $953.73 | $807.31 | |
| $559.04 | $853.17 | $991.87 | $822.72 | |
| $542.27 | $869.51 | $1,017 | $846.10 | |
| $542.27 | $880.21 | $1,028 | $852.53 | |
| $558.54 | $899.43 | $1,080 | $882.91 | |
| $569.71 | $923.58 | $1,112 | $900.46 | |
| $558.32 | $945.77 | $1,157 | $922.67 | |
| $575.07 | $969.74 | $1,226 | $935.91 | |
| $586.57 | $988.47 | $1,202 | $952.30 | |
| $592.43 | $1,020 | $1,262 | $976.28 | |
| $592.43 | $1,049 | $1,337 | $1,002 |
Research Provenance
References & Context
This Regeneron Pharmaceuticals consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2007-01-01–2026-01-01, 20 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).